Date: <u>30/May/2022</u>
our Name:Kimitaka Akaike
Manuscript Title: Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung
lisease who received pulmonary resection
Manuscript number (if known):JTD-22-604

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> None	
3	Royalties or licenses	XNone	
4	Consulting fees	_ <b>X</b> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_ <b>X</b> None	
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or	_XNone	
10	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_XNone	
11	Stock or stock options	_ <b>X</b> None	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other services		
13	Other financial or non- financial interests	_XNone	
Plea	ase summarize the above co	nflict of interest in the following bo	ox:
ľ	None		

Pate: 30/May/2022	_			
our Name: Koichi Saruwatari	_			
Nanuscript Title: Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung				
disease who received pulmonary resection				
Nanuscript number (if known): JTD-22-604				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for lectures, presentations,	XNone
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert testimony	XNone
	,	
7	Support for attending meetings and/or travel	_ <b>X</b> None
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	V None
9	Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	_ XNone
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_ <b>X</b> None
12	Receipt of equipment,	X None
12	materials, drugs, medical	_ XNone
	writing, gifts or other	
	services	
13	Other financial or non- financial interests	XNone
	illianciai iliterests	
Plea	ase summarize the above co	nflict of interest in the following box:
N	None	

Date:30/May	/2022			
Your Name:	Ryohei Matsushima			
Manuscript Title:_	Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung			
lisease who received pulmonary resection				
Manuscript numb	er (if known): JTD-22-604			
•				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone	
	processing charges, etc.)  No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for lectures, presentations,	XNone
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert testimony	XNone
	,	
7	Support for attending meetings and/or travel	_ <b>X</b> None
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	V None
9	Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	_ XNone
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_ <b>X</b> None
12	Receipt of equipment,	X None
12	materials, drugs, medical	_ XNone
	writing, gifts or other	
	services	
13	Other financial or non- financial interests	XNone
	illianciai iliterests	
Plea	ase summarize the above co	nflict of interest in the following box:
N	None	

Date: <u>30/May/2022</u>				
/our Name:Kosuke Fujino	_			
Manuscript Title: Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung				
disease who received pulmonary resection				
Manuscript number (if known): JTD-22-604	_			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone	
	processing charges, etc.)  No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	_XNone	
	in item #1 above).		
3	Royalties or licenses	_XNone	
4	Consulting fees	_ <b>X</b> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_ <b>X</b> None	
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or	_XNone	
10	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_XNone	
11	Stock or stock options	_ <b>X</b> None	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other services		
13	Other financial or non- financial interests	_XNone	
Plea	ase summarize the above co	nflict of interest in the following bo	ox:
ľ	None		

Date: <u>30/May/2022</u>	2
Your Name: Jun N	Morinaga
Manuscript Title: Clinic	cal impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung
disease who received p	ulmonary resection
Manuscript number (if	known): JTD-22-604

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone	
	processing charges, etc.)  No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for lectures, presentations,	XNone
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert testimony	XNone
	,	
7	Support for attending meetings and/or travel	_ <b>X</b> None
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	V None
9	Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	_ XNone
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_ <b>X</b> None
12	Receipt of equipment,	X None
12	materials, drugs, medical	_ XNone
	writing, gifts or other	
	services	
13	Other financial or non- financial interests	XNone
	illianciai iliterests	
Plea	ase summarize the above co	nflict of interest in the following box:
N	None	

Date:	30/May/2022
Your Nar	ne: Seitaro Oda
Manuscr	pt Title: Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung
disease v	vho received pulmonary resection
Manuscr	pt number (if known): JTD-22-604

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	XNone
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert testimony	XNone
	,	
7	Support for attending meetings and/or travel	_ <b>X</b> None
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	V None
9	Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	_ XNone
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_ X None
12	Receipt of equipment,	X None
12	materials, drugs, medical	_ XNone
	writing, gifts or other	
	services	
13	Other financial or non- financial interests	XNone
	illianciai iliterests	
Plea	ase summarize the above co	nflict of interest in the following box:
N	None	

	80/May/2022 e: Hiroshi Takahashi
/lanuscript	t Title: Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung
lisease wh	o received pulmonary resection
/lanuscript	t number (if known): JTD-22-604

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_ <b>X</b> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_ <b>X</b> None	
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or	_XNone	
10	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_XNone	
11	Stock or stock options	_ <b>X</b> None	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other services		
13	Other financial or non- financial interests	_XNone	
Plea	ase summarize the above co	nflict of interest in the following bo	ox:
ľ	None		

Date:30/May	/2022
Your Name:	Shinya Shiraishi
Manuscript Title:_	Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung
disease who receive	ved pulmonary resection
Manuscript numb	er (if known): JTD-22-604

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_ <b>X</b> None	
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or	_XNone	
10	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_XNone	
11	Stock or stock options	_ <b>X</b> None	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other services		
13	Other financial or non- financial interests	_XNone	
Plea	ase summarize the above co	nflict of interest in the following bo	ox:
ľ	None		

Date:30/May/2022
Your Name: Hiroko Okabayashi
Manuscript Title: Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung
disease who received pulmonary resection
Manuscript number (if known): JTD-22-604

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	30 Months
3	Royalties or licenses	_XNone	
4	Consulting fees	<b>X</b> None	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	XNone	
	,		
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or	_ XNone	
	pending		
9	Participation on a Data	V None	
9	Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_ X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	_ XNone	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	XNone	
	illianciai iliterests		
Plea	Please summarize the above conflict of interest in the following box:		
N	None		

Date:30/May	/2022	
Your Name:	Shohei Hamada	
Manuscript Title:_	Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung	
disease who received pulmonary resection		
Manuscript numb	er (if known): JTD-22-604	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone	
	processing charges, etc.)  No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	XNone	
	,		
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or	_ XNone	
	pending		
9	Participation on a Data	V None	
9	Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_ <b>X</b> None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	_ XNone	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	XNone	
	illianciai iliterests		
Plea	Please summarize the above conflict of interest in the following box:		
N	None		

Date:30/May/2022
Your Name: Yusuke Tomita
Manuscript Title: Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung
disease who received pulmonary resection
Manuscript number (if known): JTD-22-604

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	XNone	
	,		
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or	_ XNone	
	pending		
9	Participation on a Data	V None	
9	Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_ <b>X</b> None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	_ XNone	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	XNone	
	illianciai iliterests		
Plea	Please summarize the above conflict of interest in the following box:		
N	None		

Date:30,	/May/2022
Your Name:_	Aiko Masunaga
Manuscript 1	Title: Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung
disease who	received pulmonary resection
Manuscript r	number (if known): JTD-22-604

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone	
	processing charges, etc.)  No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	XNone	
	,		
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or	_ XNone	
	pending		
9	Participation on a Data	V None	
9	Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_ <b>X</b> None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	_ XNone	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	XNone	
	illianciai iliterests		
Plea	Please summarize the above conflict of interest in the following box:		
N	None		

Date: <u>30/May</u>	/2022				
Your Name:	Sho Saeki				
Manuscript Title:_	Clinical impact of	of SUV <sub>max</sub> of interstitial	lesions in lung cand	cer patients with inte	erstitial lung
disease who recei	ved pulmonary r	esection			_
Manuscript numb	er (if known):	JTD-22-604			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	30 Months
3	Royalties or licenses	_XNone	
4	Consulting fees	<b>X</b> None	

5	Payment or honoraria for lectures, presentations,	XNone
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert testimony	XNone
	,	
7	Support for attending meetings and/or travel	_ <b>X</b> None
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	V None
9	Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	_ XNone
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_ X None
12	Receipt of equipment,	X None
12	materials, drugs, medical	_ XNone
	writing, gifts or other	
	services	
13	Other financial or non- financial interests	XNone
	illianciai iliterests	
Plea	ase summarize the above co	nflict of interest in the following box:
N	None	

Date:30/May	/2022
Your Name:	Koei Ikeda
Manuscript Title:_	Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung
disease who receive	ved pulmonary resection
Manuscript number	er (if known): JTD-22-604

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for lectures, presentations,	XNone
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert testimony	XNone
	,	
7	Support for attending meetings and/or travel	_ <b>X</b> None
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	V None
9	Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	_ XNone
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_ X None
12	Receipt of equipment,	X None
12	materials, drugs, medical	_ XNone
	writing, gifts or other	
	services	
13	Other financial or non- financial interests	XNone
	illianciai iliterests	
Plea	ase summarize the above co	nflict of interest in the following box:
N	None	

Date:30/May	/2022
Your Name:	Hidenori Ichiyasu
Manuscript Title:_	Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung
disease who recei	ved pulmonary resection
Manuscript numb	er (if known): JTD-22-604

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	30 Months
3	Royalties or licenses	_XNone	
4	Consulting fees	<b>X</b> None	

5	Payment or honoraria for lectures, presentations,	XNone
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert testimony	XNone
	,	
7	Support for attending meetings and/or travel	_ <b>X</b> None
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	V None
9	Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	_ XNone
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_ X None
12	Receipt of equipment,	X None
12	materials, drugs, medical	_ XNone
	writing, gifts or other	
	services	
13	Other financial or non- financial interests	XNone
	illianciai iliterests	
Plea	ase summarize the above co	nflict of interest in the following box:
N	None	

Date:	30/May/2022				
Your Name	e: Makoto Suzuk	<u>i</u>			
Manuscrip	t Title: Clinical impact of	of SUV <sub>max</sub> of interstitial	lesions in lung cancer	patients with interstitial lur	ng
disease wh	no received pulmonary re	esection			_
Manuscrip	t number (if known):	JTD-22-604			
•	-				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	XNone
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert testimony	XNone
	,	
7	Support for attending meetings and/or travel	_ <b>X</b> None
8	Patents planned, issued or	_ XNone
	pending	
9	Participation on a Data	V None
9	Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	_ XNone
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_ <b>X</b> None
12	Receipt of equipment,	X None
12	materials, drugs, medical	_ XNone
	writing, gifts or other	
	services	
13	Other financial or non- financial interests	XNone
	illianciai iliterests	
Plea	ase summarize the above co	nflict of interest in the following box:
N	None	

ate: <u>30/May/2022</u>					
Your Name:	Takuro Sakagami				
Manuscript Title:_	Clinical impact of SUV <sub>max</sub> of interstitial lesions in lung cancer patients with interstitial lung				
disease who received pulmonary resection					
Manuscript numb	er (if known): JTD-22-604				
•					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	XNone			
	speakers bureaus,				
	manuscript writing or educational events				
6	Payment for expert testimony	XNone			
	,				
7	Support for attending meetings and/or travel	_ <b>X</b> None			
8	Patents planned, issued or	_ XNone			
	pending				
9	Participation on a Data	V None			
9	Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	_ XNone			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	_ <b>X</b> None			
12	Receipt of equipment,	X None			
12	materials, drugs, medical	_ XNone			
	writing, gifts or other				
	services				
13	Other financial or non- financial interests	XNone			
Please summarize the above conflict of interest in the following box:					
None					